Molecular mechanism underlying the selective attack of trehalose lipids on cancer cells as revealed by coarse-grained molecular dynamics simulations.
Cancer therapy
Membrane curvature
Membrane fusion
Phosphatidylinositol
Phosphatidylserine
Trehalosemonomyristate
Journal
Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
31
08
2020
revised:
03
01
2021
accepted:
05
01
2021
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
The present study indicated that the mixed lipid bilayer of dimyristoylphosphatidylcholine (DMPC) and trehalosemonomyristate (TreC14) interacted strongly with the plasma membrane of cancer cells, and not that of normal cells, when the composition of TreC14 was 70%, as revealed by coarse-grained molecular dynamics simulations. These results were consistent with those of previous experimental studies, indicating that DMPC/TreC14 mixed liposomes (DMTreC14) with TreC14 composition at 70% exhibited a strong anti-cancer effect without affecting normal cells. The simulations also revealed that lipids with highly hydrophilic and bulky head groups, such as TreC14, phosphatidylinositol (PI), and phosphatidylserine (PS), showed the tendency to accumulate. This caused both the DMTreC14 and cancer cell membranes to bend into large positive curvatures, resulting in tight contact between them. In contrast, no apparent interaction between the DMTreC14 and normal cell membranes was observed because PI and PS did not exist in the extracellular monolayer of the normal cell membrane.
Identifiants
pubmed: 33521337
doi: 10.1016/j.bbrep.2021.100913
pii: S2405-5808(21)00007-8
pmc: PMC7820381
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100913Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Curr Opin Cell Biol. 2002 Aug;14(4):488-95
pubmed: 12383801
Anticancer Res. 2013 Nov;33(11):4727-40
pubmed: 24222107
Biol Pharm Bull. 2013;36(8):1258-62
pubmed: 23697966
Biochim Biophys Acta. 2011 Nov;1808(11):2638-45
pubmed: 21810406
Annu Rev Physiol. 1992;54:579-99
pubmed: 1562184
Neoplasia. 2011 Apr;13(4):299-308
pubmed: 21472134
Anticancer Res. 2017 Nov;37(11):6133-6139
pubmed: 29061794
Biochim Biophys Acta. 1982 Jun 14;688(2):495-504
pubmed: 7104337
J Chem Phys. 2015 Dec 28;143(24):243112
pubmed: 26723597
Science. 1977 Feb 25;195(4280):743-53
pubmed: 402030
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7235-40
pubmed: 11404463
ACS Appl Mater Interfaces. 2017 Jul 19;9(28):24126-24139
pubmed: 28632387
Adv Carbohydr Chem Biochem. 1974;30:227-56
pubmed: 4377836
J Pharm Sci. 2011 Jun;100(6):2020-53
pubmed: 21337544
Arch Microbiol. 2000 Oct;174(4):217-24
pubmed: 11081789
Glycobiology. 2003 Apr;13(4):17R-27R
pubmed: 12626396
Sci Rep. 2019 Apr 4;9(1):5627
pubmed: 30948733
Front Pharmacol. 2017 Jan 23;8:12
pubmed: 28167913
Chembiochem. 2016 Aug 17;17(16):1541-9
pubmed: 27252026
Cancer Res. 2002 Nov 1;62(21):6132-40
pubmed: 12414638
Bioorg Med Chem Lett. 2016 Jan 15;26(2):301-305
pubmed: 26711146
Trends Biotechnol. 1998 Nov;16(11):460-8
pubmed: 9830154
Biomacromolecules. 2013 Aug 12;14(8):2561-9
pubmed: 23777473
ACS Cent Sci. 2019 Apr 24;5(4):644-650
pubmed: 31041384
J Am Chem Soc. 2012 May 23;134(20):8474-9
pubmed: 22519420
Crit Rev Biochem Mol Biol. 2009 Sep-Oct;44(5):278-91
pubmed: 19780639
Chem Phys Lipids. 2018 Nov;216:80-90
pubmed: 30273546
J Phys Chem B. 2007 Jul 12;111(27):7812-24
pubmed: 17569554